References
- Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018. doi: 10.1155/2018/5253623.
- Donati M, Conforti A, Lenti MC, Capuano A, Motola D, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016;82(1):238–248.
- Schmeltzer PA, Kosinski AS, Kleiner DE, et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 2016;36(4):603–609. doi: 10.1111/liv.13032.
- Lexicomp Online®, Lexi-Drugs®. Hudson(OH): Lexi-Comp, Inc.; 2017.
- García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27(9):780–789. doi: 10.1111/j.1365-2036.2008.03655.x.
- Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009;104(2):356–362. doi: 10.1038/ajg.2008.149.
- Rochon J, Protiva P, Seeff LB, et al. Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology 2008;48(4):1175–1183. doi: 10.1002/hep.22442.
- Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26(3):664–669. doi: 10.1002/hep.510260319.